Valeant Pharmaceuticals International Revenue and Competitors

Bridgewater, NJ USA

Location

$1.2B

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Valeant Pharmaceuticals International's estimated annual revenue is currently $460.5M per year.(i)
  • Valeant Pharmaceuticals International's estimated revenue per employee is $321,600
  • Valeant Pharmaceuticals International's total funding is $1.2B.

Employee Data

  • Valeant Pharmaceuticals International has 1432 Employees.(i)
  • Valeant Pharmaceuticals International grew their employee count by 1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

Valeant Pharmaceuticals International (NYSE: VRX) is a global, research-based, specialty pharmaceutical company that discovers, develops, manufactures and markets pharmaceutical products, primarily in the areas of neurology, dermatology and infectious disease. Valeant has made rapid strides under a new management team that laid out a strategic vision with a renewed focus on its specialty pharmaceuticals business, and has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.

keywords:N/A

$1.2B

Total Funding

1432

Number of Employees

$460.5M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Valeant Pharmaceuticals International's People

NameTitleEmail/Phone
1
Senior Manager, Market Access TrainingReveal Email/Phone
2
Director Medical Communications, Pharmaceutical Medical AffairsReveal Email/Phone
3
Business AnalystReveal Email/Phone
4
CMC Manager, Regulatory AffairsReveal Email/Phone
5
Clinical Trial ManagerReveal Email/Phone
6
Assitant DirectorReveal Email/Phone
7
Director, Corporate Audit ServicesReveal Email/Phone
8
Sr. Director, Analytical DevelopmentReveal Email/Phone
9
Manager, Access SolutionsReveal Email/Phone
10
Sr. Specialist, Regulatory AffairsReveal Email/Phone

Valeant Pharmaceuticals International News

2022-04-17 - Atopic Dermatitis Market Size, Share, Growth| Data Analysis ...

... Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International,.

2022-04-17 - Bill Ackman bet $1.1 billion on Netflix months ago and now he’s taking a beating. But the famed investor has doubled down before—and come out ahead

In early 2015, he made an ill-fated bet on Valeant Pharmaceuticals International, which resulted in two years of double-digit portfolio...

2022-04-17 - Global Anti-Infective Ophthalmic Market 2022 Growth Analysis ...

Novartis; Allergan; Valeant Pharmaceuticals; Santen Pharmaceutical; Lupin Pharmaceuticals; Apotex; Akorn. Customization of the Report: This report can be...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$300M14776%N/A
#2
$276.2M1805-2%$68M
#3
$700.7M2043N/AN/A
#4
$1325.3M5259N/AN/A
#5
$2070M53608%$854M